Precision Radiotherapy Enabled by Molecular MRI

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study ID
NCT07512154
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Amide proton transfer radiotherapy — RADIATION
    New APT-RT regimen
  • Standard radiotherapy — RADIATION
    Standard two-phase RT

Study Details

This is a research study to determine if a novel molecular magnetic resonance imaging (MRI) technique, called amide proton transfer (APT) imaging, is useful in identifying the most aggressive areas of tumor needed for radiotherapy of brain tumors.

Key Dates

Start date
Apr 29, 2026
Status verified
May 2026
Primary completion
May 31, 2031
Completion
May 31, 2032

Study Design

Enrollment
20 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Amide proton transfer radiotherapy (APT-RT)
    Amide proton transfer radiotherapy (APT-RT) is weighted imaging that may enhance visualization of tumor infiltration and could reduce the risk of radiation toxicity while still effectively irradiating the tumor.
  • Active Comparator: Standard radiotherapy (RT)

Primary Outcome Measure

Change in APTw signal (Efficacy of APT-RT) [ Time Frame: From baseline to 4 weeks post completion of RT. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Johns Hopkins UniversityBaltimoreMaryland21287
Dana B Kaplin, MPH
[email protected]
410-614-3950

Find similar trials in Baltimore, MD

By condition
Brain cancer
By specialty
OncologyNeuro-oncology
By research site
Johns Hopkins University· Baltimore, MD

Related Studies